Aperture

Aperture provides real-time patient insights at the moment of diagnosis, enabling biopharmaceutical companies to rapidly advance precision drug development and generate substantial real-world evidence to support market access strategies. Drawing from Proscia's global network of diagnostic labs that review over 8 million cases annually on the Concentriq enterprise pathology platform, Aperture unlocks critical pathology data necessary for developing innovative therapies.

The system transforms routine pathology diagnoses into actionable insights without altering existing workflows, allowing labs to play a significant role in the development of novel therapies. By connecting to an expansive diagnostic network, Aperture provides access to a multimodal database filled with over 12 million digitized slides, fostering opportunities for business growth among academic medical centers, healthcare systems, and reference laboratories.

Key Features

• Real-Time Insights: Identifies patients at the earliest diagnosis phase, days or weeks ahead of other resources like EHRs or genomics, aiding in swift provider notification before treatment decisions are finalized.
• Diverse Diagnostic Network: Involves a vast network that performs over 8 million diagnoses annually, offering deep, diverse data access.
• AI-Enriched Data: Facilitates precise patient matching through comprehensive profiles enriched by AI-derived tissue images, biomarkers, molecular results, and clinical data.

The tool aids in uncovering diagnostic signals to propel discovery, monitoring biomarker prevalence across varied populations, and identifying novel biomarkers for AI-based companion diagnostics. It enhances clinical trial processes by optimizing trial design and accelerating patient recruitment, providing crucial data that aids in the refinement of trial criteria and improves enrollment efficiency. Furthermore, Aperture supports regulatory activities by supplying real-world evidence required for regulatory submissions and facilitating label expansions.

Functioning through the Concentriq Enterprise Pathology Platform, a central component for leading pharmaceutical R&D and diagnostic workflows, Aperture is powered by AI models that enhance biomarker detection and trial matching.

Available to select Proscia Concentriq customers, the system is a pivotal tool for those looking to leverage diagnostic data for improved precision medicine outcomes.